Timothy S. Thorpe

Array ( [id] => 4177405 [patent_doc_number] => 06019987 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-02-01 [patent_title] => 'Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof' [patent_app_type] => 1 [patent_app_number] => 8/668560 [patent_app_country] => US [patent_app_date] => 1996-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3775 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/019/06019987.pdf [firstpage_image] =>[orig_patent_app_number] => 668560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4149059 [patent_doc_number] => 06063900 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-05-16 [patent_title] => 'Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof' [patent_app_type] => 1 [patent_app_number] => 8/667725 [patent_app_country] => US [patent_app_date] => 1996-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 9078 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/063/06063900.pdf [firstpage_image] =>[orig_patent_app_number] => 667725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3876069 [patent_doc_number] => 05728560 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-03-17 [patent_title] => 'Method of treating CD4+ T cell lymphopenia in immuno-compromised patients' [patent_app_type] => 1 [patent_app_number] => 8/663685 [patent_app_country] => US [patent_app_date] => 1996-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4898 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/728/05728560.pdf [firstpage_image] =>[orig_patent_app_number] => 663685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3772808 [patent_doc_number] => 05849879 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-12-15 [patent_title] => 'Methods for the diagnosis of glaucoma' [patent_app_type] => 1 [patent_app_number] => 8/645900 [patent_app_country] => US [patent_app_date] => 1996-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 13849 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/849/05849879.pdf [firstpage_image] =>[orig_patent_app_number] => 645900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3869205 [patent_doc_number] => 05824315 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-10-20 [patent_title] => 'Binding affinity of antigenic peptides for MHC molecules' [patent_app_type] => 1 [patent_app_number] => 8/640344 [patent_app_country] => US [patent_app_date] => 1996-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 11283 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/824/05824315.pdf [firstpage_image] =>[orig_patent_app_number] => 640344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3781259 [patent_doc_number] => 05840305 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-11-24 [patent_title] => 'Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity' [patent_app_type] => 1 [patent_app_number] => 8/615933 [patent_app_country] => US [patent_app_date] => 1996-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17886 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/840/05840305.pdf [firstpage_image] =>[orig_patent_app_number] => 615933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3836067 [patent_doc_number] => 05846826 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-12-08 [patent_title] => 'Isolated cytolytic T cell line specific to complexes of HLA-B44 molecules and specific nonapeptides' [patent_app_type] => 1 [patent_app_number] => 8/611273 [patent_app_country] => US [patent_app_date] => 1996-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 9 [patent_no_of_words] => 4925 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/846/05846826.pdf [firstpage_image] =>[orig_patent_app_number] => 611273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3700294 [patent_doc_number] => 05677430 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-10-14 [patent_title] => 'Antibodies directed against CD30 ligand' [patent_app_type] => 1 [patent_app_number] => 8/570923 [patent_app_country] => US [patent_app_date] => 1995-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22413 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/677/05677430.pdf [firstpage_image] =>[orig_patent_app_number] => 570923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3927447 [patent_doc_number] => 05877155 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-03-02 [patent_title] => 'Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX' [patent_app_type] => 1 [patent_app_number] => 8/556597 [patent_app_country] => US [patent_app_date] => 1995-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 14 [patent_no_of_words] => 16940 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/877/05877155.pdf [firstpage_image] =>[orig_patent_app_number] => 556597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3883673 [patent_doc_number] => 05833991 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-11-10 [patent_title] => 'Glycine-containing sequences conferring invisibility to the immune system' [patent_app_type] => 1 [patent_app_number] => 8/529190 [patent_app_country] => US [patent_app_date] => 1995-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 18397 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/833/05833991.pdf [firstpage_image] =>[orig_patent_app_number] => 529190 [rel_patent_id] =>[rel_patent_doc_number] =>)